«Application of RT-LAMP-CRISPR-Cas13a technology to the detection of OXA-48 producing Klebsiella pneumoniae»

Carbapenem-resistant pathogens have been recognized as a health concern because of their ability to cause severe infections and because they are difficult to detect in laboratories. Researchers are making great efforts to develop a diagnostic technique with high levels of sensitivity and specificity, as accurate, early diagnosis is required to prevent the spread of these microorganisms and improve the prognosis of patients. In this context, CRISPR-Cas systems are proposed as promising tools for the development of diagnostic techniques due to their high specificity: Cas13 endonuclease discriminates single nucleotide changes and displays collateral activity against single-stranded RNA molecules. This technology is usually combined with isothermal pre-amplification reactions in order to increase the sensitivity of diagnosis. We have developed an RT-LAMP-CRISPR-Cas13a-based assay for the detection of Klebsiella pneumoniae OXA-48 producer strains in clinical samples without the need for RNA extraction. The assay exhibited 100 % specificity, sensitivity, positive predictive value and negative predictive value.

[1]  Alan D. Lopez,et al.  Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis , 2022, The Lancet.

[2]  M. Tilahun,et al.  Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review , 2021, Infection and drug resistance.

[3]  J. Granados-Riverón,et al.  CRISPR/Cas13-Based Approaches for Ultrasensitive and Specific Detection of microRNAs , 2021, Cells.

[4]  Dorota Ozga,et al.  Carbapenem-Resistant Klebsiella pneumoniae Infections in ICU COVID-19 Patients—A Scoping Review , 2021, Journal of clinical medicine.

[5]  Yunsong Yu,et al.  A Global Perspective on the Convergence of Hypervirulence and Carbapenem-Resistance in Klebsiella pneumoniae. , 2021, Journal of global antimicrobial resistance.

[6]  I. Karunasagar,et al.  Detection technologies and recent developments in the diagnosis of COVID-19 infection , 2021, Applied Microbiology and Biotechnology.

[7]  A. Waisman,et al.  Extraction-free protocol combining proteinase K and heat inactivation for detection of SARS-CoV-2 by RT-qPCR , 2020, medRxiv.

[8]  Raoudha Dziri,et al.  Carbapenemase Producing Gram-Negative Bacteria in Tunisia: History of Thirteen Years of Challenge , 2020, Infection and drug resistance.

[9]  Jinming Li,et al.  CRISPR/cas systems redefine nucleic acid detection: Principles and methods , 2020, Biosensors and Bioelectronics.

[10]  J. Botella,et al.  Evaluation and improvement of isothermal amplification methods for point-of-need plant disease diagnostics , 2020, PloS one.

[11]  Junaid Kashir,et al.  Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19 , 2020, Medical Hypotheses.

[12]  A. Kostyusheva,et al.  CRISPR-Cas systems for diagnosing infectious diseases , 2020, Methods.

[13]  S. Silva,et al.  Loop-Mediated Isothermal Amplification (LAMP) for the Diagnosis of Zika Virus: A Review , 2019, Viruses.

[14]  G. Peirano,et al.  The Global Ascendency of OXA-48-Type Carbapenemases , 2019, Clinical Microbiology Reviews.

[15]  A. Caicedo,et al.  Carbapenem-Resistant Klebsiella pneumoniae: Microbiology Key Points for Clinical Practice , 2019, International journal of general medicine.

[16]  C. MacDougall,et al.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations , 2019, Current Infectious Disease Reports.

[17]  T. Naas,et al.  Evaluation of the Amplidiag CarbaR+MCR Kit for Accurate Detection of Carbapenemase-Producing and Colistin-Resistant Bacteria , 2018, Journal of Clinical Microbiology.

[18]  I. Balakrishnan,et al.  Evaluation of the EntericBio CPE assay for the detection of carbapenemase-producing organisms. , 2018, Journal of medical microbiology.

[19]  M. Bassetti,et al.  Management of KPC-producing Klebsiella pneumoniae infections. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  J. Daduang,et al.  Rapid and simple identification of carbapenemase genes, blaNDM, blaOXA-48, blaVIM, blaIMP-14 and blaKPC groups, in Gram-negative bacilli by in-house loop-mediated isothermal amplification with hydroxynaphthol blue dye , 2017, World journal of microbiology & biotechnology.

[21]  Alina Iovleva,et al.  Carbapenem-Resistant Enterobacteriaceae. , 2017, Clinics in laboratory medicine.

[22]  B. Veeraraghavan,et al.  Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat , 2016, Journal of global infectious diseases.

[23]  G. Fahle,et al.  Clinical Performance of Check-Direct CPE, a Multiplex PCR for Direct Detection of bla KPC, bla NDM and/or bla VIM, and bla OXA-48 from Perirectal Swabs , 2015, Journal of Clinical Microbiology.

[24]  R. Thomson,,et al.  Identification of Gram-Negative Bacteria and Genetic Resistance Determinants from Positive Blood Culture Broths by Use of the Verigene Gram-Negative Blood Culture Multiplex Microarray-Based Molecular Assay , 2015, Journal of Clinical Microbiology.

[25]  J. Vila,et al.  Evaluation of the eazyplex® SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals. , 2014, The Journal of antimicrobial chemotherapy.

[26]  A. Dalpke,et al.  Detection of Carbapenemases by Real-Time PCR and Melt Curve Analysis on the BD Max System , 2014, Journal of Clinical Microbiology.

[27]  A. Fluit,et al.  Multi-centre evaluation of real-time multiplex PCR for detection of carbapenemase genes OXA-48, VIM, IMP, NDM and KPC , 2014, BMC Infectious Diseases.

[28]  A. Oliver,et al.  [The threat of the carbapenemase-producing enterobacteriaceae in Spain: positioning report of the SEIMC study groups, GEIH and GEMARA]. , 2014, Enfermedades Infecciosas y Microbiologia Clinica.